我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

两种剂量阿托伐他汀对冠心病患者踝臂指数和hsCRP影响的比较

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第5期
页码:
536-539
栏目:
临床研究
出版日期:
2013-09-25

文章信息/Info

Title:
Effect of two different doses of atorvastatin on anklebrachial index and hsCRP in patients with coronary heart disease
作者:
黄 芬1; 张小蓉2; 熊晓昉3
(1.华中科技大学同济医学院附属同济医院心内科，湖北 武汉 430030；2.上海市浦东医院心内科，上海 201300；3.武汉市第三医院心内科，湖北 武汉 430060)
Author(s):
HUANG Fen1;  ZHANG Xiao rong2;  XIONG Xiao fang3
(1.Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China; 2.Department of Cardiology, Shanghai Pudong Hospital, Shanghai 201300, China; 3.Department of Cardiology, Third Hospital of Wuhan 430060, Hubei, China)
关键词:
冠状动脉疾病; 阿托伐他汀; 踝臂指数; 高敏C反应蛋白
Keywords:
coronary disease;  atorvastatin;  anklebrachial index;  highly sensitive Creactive protein
分类号:
R541.4；R972.6
DOI:
-
文献标识码:
A
摘要:
目的:观察不同剂量阿托伐他汀治疗冠心病的疗效及其对踝臂指数（ABI）和高敏C反应蛋白（hsCRP）的影响。方法： 选择冠心病患者110例，随机分为40 mg组和10 mg组，每组各55例。10 mg组予以阿托伐他汀10 mg/次，1次/晚，40 mg组予以阿托伐他汀40 mg/次，1次/晚。观察比较两组的血脂及治疗前后的ABI和hsCRP的水平。结果： 治疗后，两组的总胆固醇（TC），三酰甘油（TG）和低密度脂蛋白胆固醇（LDLC）的水平均较治疗前显著降低（P<005或P<001），高密度脂蛋白胆固醇（HDLC）水平较治疗前显著升高（P<005）；与10 mg组比较，40 mg组LDLC 较10mg组降低更显著（P<005）。hsCRP水平较治疗前也显著降低（P<001）；与10 mg组比较，40 mg组hsCRP水平下降更为显著(P<005)。而ABI水平治疗后较治疗前显著升高（P<001），与10 mg组比较，40 mg组ABI的改善更为显著(P<005)。结论： 阿托伐他汀对冠心病患者的ABI和hsCRP改善明显，而且40 mg组改善更显著。
Abstract:
AIM:To compare the influence of two different doses of atorvastatin on anklebrachial index (ABI) and highly sensitive Creactive protein (hsCRP) in patients with coronary heart disease (CHD). METHODS: One hundred and ten patients with CHD were randomly divided into observation group and control group, with 55 patients in each group. Conventional treatment for CHD was carried out in both groups for 6 months but at different doses: 10 mg/day atorvastatin daily in one group and 40 mg/day atorvastatin daily in the other group. Serum lipid, ABI and hsCRP before and after treatment were observed in the two groups. RESULTS: After treatment, TC, TG and LDLC levels in both groups decreased significantly (P<005 or P<001), whereas levels of HDLC were significantly elevated (P<005). Atorvastatin treatment group receiving 40 mg/day achieved a significantly better lowering of LDLC than the group receiving 10 mg/day atorvastatin (P<005). The hsCRP levels in both groups were significantly lower than before treatment (P<001), but patients treated with 40 mg/day atorvastatin had significantly lower hsCRP level than patients treated with 10 mg/day atorvastatin (P<005). After 6 months, a significant improvement in ABI was observed in both groups (P<001) but the improvement in the group receiving 40 mg/day atorvastatin was significantly better than in the group receiving 10 mg/day atorvastatin (P<005). CONCLUSION: Atorvastatin improves ABI and decreases hsCRP serum concentration in patients with coronary heart disease; treatment with 40 mg/day atorvastatin is more effective.

参考文献/References

[1]Weatherley BD,Nelson JJ,Heiss G,et al.The association of the anklebrachial index with incident coronary heart disease:the Atherosclerosis Risk In Communities (ARIC) study, 1987-2001[J].BMC Cardiovasc Disord,2007,7:3.
[2]SicrasMainar A,PlanasComes A,FriasGarrido X,et al.Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease[J].J Clin Pharm Ther,2012,37(4):441-447.
[3]Cheng TO.Increasing dosage of statins in patients with coronary heart disease in China:a note of caution[J].Int J Cardiol,2012,154(1):1.
[4]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atovastatin in patients with stable coronary disease[J].N Engl J Med,2005,352(14):1425-1435.
[5]Cannon CP,Braunwald E,McCabe CH,et al.Pravastatin or atorvastatin evaluation and unfection therapythrombolysIsin myocardial infarction22 investigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med,2004,350(15):1495-1504.
[6]Silva M,Matthews ML,Jarvis C,et al.Meta analysis of druginduced adverse events associated with intensivedose statin therapy[J].Clin Ther,2007,29(2):253-260.
[7]Spector R,Snapinn SM.Statins for secondary prevention of cardiovascular disease: the right dose[J].Pharmacology,2011,87(1-2):63-69.
[8]Blaha MJ,Budoff MJ,DeFilippis AP,et al.Associations between C-reactive protein, coronary artery calcium,and cardiovascular events:implications for the JUPITER population from MESA, a populationbased cohort study[J].Lancet,2011,378(9792):684-692.
[9]Jialal I,Stein D,Balis D,et al.Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive Creactive protein levels[J].Circulation,2001,103(15):1933-1935.
[10]Rider PM,Rifai N,Clearfield M,et al.For the airforce/texas coronary atherosclerosis prevention study investigators: measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[J].N Engl J Med,2001,344(26):1959-1965.
[11]全文超,杨承健,徐欣,等.瑞舒伐他汀对高血压病合并高血脂症患者超敏C 反应蛋白的影响[J].现代医学,2009,37(6):426-428.
[12]Aboyans V,Criqui MH,Abraham P,et al.Measurement and interpretation of the anklebrachial index: a scientific statement from the American Heart Association[J].Circulation,2012,126(24):2890-2909.
[13]Ro DH,Moon HJ,Kim JH,et al.Photoplethysmography and continuouswave Doppler ultrasound as a complementary test to anklebrachial index in detection of stenotic peripheral arterial disease[J].Angiology,2013,64(4):314-320.

备注/Memo

备注/Memo:
收稿日期：2013-02-25.通讯作者：熊晓昉，主治医师，主要从事冠心病发病机制及治疗研究 Email：xxf104622@163.com 作者简介：黄芬，主治医师，博士 Email：huangfen0622@yahoo.com.cn
更新日期/Last Update: 2013-09-30